R and d process in pharmaceutical industry pharma company management ppt template

So basically there's five stages you gotta know. Drug discovery kicks things off - finding compounds that might actually work. Then you've got preclinical testing, which is all the lab work and animal studies before touching humans. Clinical trials are next - three phases of human testing, and honestly this is where your budget goes to die. Takes forever too. After that mess, you submit for FDA approval. Oh and once it's on shelves, there's post-market surveillance to watch for problems. We're talking 10-15 years start to finish, billions in costs. My advice? Whatever timeline you're thinking, double it. Delays happen constantly in pharma.

Ugh, compliance adds like 10-15 years to your whole timeline. First you're stuck doing preclinical studies, then waiting around for FDA approval before each trial phase. Phase III is the worst - 3-4 years because you need thousands of patients to prove it actually works and won't kill anyone. The paperwork is absolutely brutal too. But honestly? Talk to regulators way earlier than you think. Don't be that person who waits until Phase III to have your first real conversation with them. Start during Phase II and you'll dodge some expensive headaches later. Trust me on this one.

So preclinical is basically proving your drug won't kill people before you test it on actual humans. You're checking toxicity, how it moves through the body, all that fun stuff. The failure rate is still pretty rough though - like, way higher than you'd expect. FDA won't even look at you without solid preclinical data first. My advice? Really nail down your pharmacokinetics early because fixing that later is a nightmare. It's your proof of concept phase, just with a lot more lab work and animal studies than you probably want to think about.

So they basically score everything on spreadsheets - market size, how likely it'll actually work, development costs. The business dev people are obsessed with this stuff. But honestly? The science teams' hunches carry weight too. They look at unmet medical need, what competitors are doing, patent timelines. Oh and regulatory shortcuts matter huge - orphan drugs get fast-tracked which is why you see so many rare disease plays now. If you're trying to sell a candidate internally, lead with the money opportunity first. Then hit them with your best preclinical data to back it up.

Ugh, patient recruitment will destroy your soul - finding the right people is brutal and half of them drop out anyway. Regulatory stuff multiplies like rabbits, I swear. Then you've got sites that just ignore protocols completely, which screws up all your data. Budget? Yeah, forget staying on track. Something always breaks that you never saw coming. Managing multiple sites is chaos since everyone does things differently. Honestly, the coordination alone will age you. Build extra time into recruitment from day one. Also, drill your sites hard on training upfront - trust me, it's worth the pain early on versus dealing with disasters later.

Dude, pharma companies are using AI to completely flip how they develop drugs. Instead of spending years identifying targets and testing compounds, machine learning can crunch through massive datasets in months. The algorithms spot patterns we'd totally miss and predict which molecules actually have a chance. Clinical trials get optimized too - honestly, some of these timelines are insane compared to what they used to be. Best part? You fail early and cheap, then pour money into the stuff that'll actually work. It's wild how much faster everything moves now.

Drug testing is basically preclinical stuff first - lab work, animal studies, the usual. Then you've got three human trial phases. Phase I is just "will this kill you" testing with small groups. Phase II ramps up to a few hundred people to see if it actually works. Phase III is the big one - thousands of patients to prove it beats current treatments. Takes forever honestly, like 10-15 years and costs are insane. But that's how we avoid another thalidomide situation. If you're looking at pharma stocks, check what phase their main drugs are in - tells you everything about timeline and risk.

Honestly, these partnerships are pretty solid. Universities crush it at basic research - stuff companies don't have time for. You get access to grad students and postdocs who think differently than your internal teams. The funding flows both ways too, which is nice. Companies share costs and risk on early-stage work, while unis get real-world applications for their discoveries. My old lab did a few of these deals and they worked out well. If you're trying to beef up your R&D pipeline, I'd definitely hit up local research universities in whatever therapeutic areas you're focused on.

Dude, patient input is everything. It'll literally shape your whole trial design - which indications to chase, what endpoints actually matter. We think we know what symptoms patients care about, but we're usually wrong lol. I've watched companies completely pivot after getting early patient feedback, and it saved them from building something nobody wanted. Patients tell you the real unmet needs, what side effects they'll tolerate, even basic stuff like how often they want to take pills. Start patient advisory boards early and don't ignore what they say.

Look, IP is what makes the whole pharma industry work financially. Companies won't drop billions on R&D if generics can just copy their work immediately - makes total sense, right? Patents give you about 20 years of protection, but here's where it gets tricky. You're filing way early in development, so once your drug actually launches, you've probably only got 8-12 years left to make your money back. That's honestly why these companies get so obsessive about timing their patents perfectly. Bottom line: you've gotta sync up your IP strategy with your development timeline or you're leaving money on the table.

So pharma R&D is changing pretty fast right now. AI's making drug discovery way quicker - like, they can actually predict what'll work before spending years testing. Personalized medicine is everywhere now, tons of targeted therapies based on your specific genetics. Companies are also using real patient data instead of just clinical trials, which honestly makes way more sense. Oh and rare diseases are having a moment since the FDA made approval easier. Might be worth seeing if any of this fits your current stuff - could save you time down the road.

Dude, it's all about market dynamics - that's what decides where you throw your R&D money and which projects actually happen. You're always checking what competitors are doing, watching for patent cliffs, figuring out unmet needs. Basically like chess but everyone's playing at once. Sometimes a competitor drops something similar to your Phase II drug and you've gotta decide - pivot or go harder? Really depends if you can differentiate enough. I've seen companies get burned by not staying flexible with their portfolios. You gotta keep reassessing when the market shifts or new players jump in.

Biomarkers are total game-changers in drug development. You can identify which patients will actually respond to treatment, plus track whether your drug is doing what it's supposed to. They're basically measurable signals - blood tests, tissue samples, imaging stuff - that show what's happening inside the body. Super important for personalized medicine too. Regulators eat this data up because it makes your clinical trials way more solid and can fast-track approvals. Honestly, I'd build your biomarker strategy from day one. Saves you tons of headaches later, trust me.

Look, you gotta be smart about where you dump your R&D money. Pick areas where you're already strong instead of throwing cash everywhere - that never works. Partner up or license stuff to spread the risk around. Digital tools and AI will speed up your discovery process, which honestly saves a ton of time. Build a mix where safer bets pay for your crazy experimental projects. I'd start by going through your current pipeline first. See what actually matches what you're good at. The portfolio approach is huge - some projects fund others. Makes way more sense than putting all eggs in one basket, you know?

Ok so the main things - informed consent is huge, obviously. Participants need to actually get what they're signing up for and know they can bail whenever. Safety monitoring comes first too, like having solid plans for when to pull the plug if stuff goes sideways. Don't just recruit whoever's easiest to find - you want diverse groups that actually represent real patients. And seriously, document literally everything because data integrity will make or break you. No hiding the bad results when they happen (and they will). Honestly, I always think would I put my own mom in this study? That's your gut check right there.